Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
As of 2025, retatrutide remains an investigational compound and has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Preventive Services Task Force, an influential medical group whose policies often guide insurance coverage, chose not to recommend weight loss medications for children in newly-released guidelines for treating obesity, saying there is not enough long-term data to recommend the medications
Notes Injections are subcutaneous in belly fat Best to inject in the AM in a fasted state For best results, use long term (years) Do not expect to see results until 6-12 months
In particular, Ricciardi et al
Research dosing protocols The clinically validated dose is 2 mg Tesamorelin subcutaneously once daily
US$ 20.76
US$ 29.66
US$ 25.10
US$ 20.12
US$ 21.76
